A study published in Clinical Genitourinary Cancer last month describes the real world clinical outcomes of treating advanced renal cell carcinoma (RCC) patients with pazopanib after they had already been treated with immunotherapy.
A total of 258 patients were enrolled in the study and had been treated with immunotherapy before pazopanib as follows: nivolumab (68%), nivolumab plus ipilimumab (14%), pembrolizumab (12%), and ipilimumab (3%). Overall, the median duration of pazopanib treatment was 13.4 months. The median progression-free survival with pazopanib after immunotherapy was 13.5 months. The estimated overall survival rate of pazopanib after immunotherapy at 6 and 12 months was 93% and 89%, respectively. 42% of patients reported an adverse event, the most frequent being fatigue (29%) and diarrhoea (14%). There were no signs of liver toxicity.
In conclusion, second-line pazopanib after previous immunotherapy was well-tolerated and effective for patients with advanced RCC.